4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001714899-24-000206
President and CEO sold 40,000 shares at $27.69 ($1,107,600)
- President and CEO acquired 40,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Watts Ryan J. · President and CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-10-18 | Exercise or conversion : show line 1 in the form 10b5-1 | +40,000 | $0.68 | $27,200 | 275,807 | D |
| 2024-10-18 | Sale : show line 2 in the form 10b5-1 | −40,000 | $27.69 | $1,107,600 | 235,807 | D |
| Open-market sales · 40,000 sh · avg $27.69 · $1,107,600 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-10-18 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −40,000 | 1,078,091 | D |
Loading xslF345X05/wk-form4_1729629050.xml…